Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E Mutation”

130 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 130 results

Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Testing effectiveness (Phase 2)UnknownNCT02202200
What this trial is testing

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Who this might be right for
Melanoma BRAF V600E/K MutatedCDNKN2A Loss Defined
Assistance Publique - Hôpitaux de Paris 40
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Testing effectiveness (Phase 2)UnknownNCT05641493
What this trial is testing

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Henlius Biotech 49
Testing effectiveness (Phase 2)UnknownNCT05528406
What this trial is testing

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Henlius Biotech 30
Not applicableStudy completedNCT03363347
What this trial is testing

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Heidelberg University 25
Testing effectiveness (Phase 2)Looking for participantsNCT06640166
What this trial is testing

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Who this might be right for
Colorectal CarcinomaColorectal NeoplasmsColorectal Tumor+7 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 25
Testing effectiveness (Phase 2)Study completedNCT03915951
What this trial is testing

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 98
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526782
What this trial is testing

ENCOrafenib With Binimetinib in bRAF NSCLC

Who this might be right for
Non Small Cell Lung CancerBRAF V600E
Intergroupe Francophone de Cancerologie Thoracique 119
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)UnknownNCT05092802
What this trial is testing

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Who this might be right for
Brain Tumor, Primary
Shanghai Henlius Biotech 40
Testing effectiveness (Phase 2)Study completedNCT01750918
What this trial is testing

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Who this might be right for
Cancer
Novartis Pharmaceuticals 166
Large-scale testing (Phase 3)UnknownNCT05540951
What this trial is testing

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Fudan University 78
Large-scale testing (Phase 3)Not Yet RecruitingNCT06819605
What this trial is testing

Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma

Who this might be right for
Ameloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 46
Large-scale testing (Phase 3)Study completedNCT02928224
What this trial is testing

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutant Metastatic Colorectal Cancer
Pfizer 702
Testing effectiveness (Phase 2)Ended earlyNCT04310397
What this trial is testing

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Who this might be right for
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Looking for participantsNCT05503797
What this trial is testing

Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Who this might be right for
Cancer Harboring BRAF AlterationsHGGLGG+1 more
Fore Biotherapeutics 254
Load More Results